MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
OptimizeRx Corporation Gross Profit 2011-2026 | OPRX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit OptimizeRx Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.9 M | 39 M | 35.6 M | 24.1 M | 15.4 M | 12.2 M | 5.95 M | 4.34 M | 3.6 M | 3.28 M | 3.19 M | 2.05 M | 1.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.9 M | 1.11 M | 14.8 M |
Quarterly Gross Profit OptimizeRx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.5 M | 18.6 M | 13.3 M | - | 13.4 M | 11.7 M | 12.2 M | - | 9.8 M | 7.82 M | 7.43 M | - | 9.42 M | 8.99 M | 8.1 M | - | 9.08 M | 8.04 M | 6.12 M | - | 6.01 M | 5.14 M | 4.34 M | - | 3.02 M | 4.32 M | 3.63 M | - | 3.15 M | 2.86 M | 2.1 M | - | 1.4 M | 1.26 M | 770 K | - | 1.06 M | 990 K | 867 K | - | 963 K | 823 K | 731 K | - | 861 K | 697 K | 728 K | - | 844 K | 1.04 M | 653 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 M | 653 K | 5.38 M |
Gross Profit of other stocks in the Health information services industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
4.57 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
136 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
858 M | - | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
113 M | - | - | $ 9.03 B | USA |
 |
Accolade
ACCD
|
58.8 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
94.7 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
216 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
500 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
333 M | $ 3.97 | 3.39 % | $ 372 M | USA |
 |
Akerna Corp.
KERN
|
5.55 M | - | - | $ 161 M | USA |
 |
Health Catalyst
HCAT
|
79.6 M | $ 2.29 | -3.18 % | $ 138 M | USA |
 |
HealthStream
HSTM
|
150 M | $ 21.16 | -1.44 % | $ 643 M | USA |
 |
iCAD
ICAD
|
16.6 M | - | - | $ 102 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
620 M | - | -10.39 % | $ 886 M | USA |
 |
HealthEquity
HQY
|
163 M | $ 84.44 | -2.3 % | $ 7.23 B | USA |
 |
American Well Corporation
AMWL
|
68.9 M | $ 4.92 | -0.2 % | $ 73.8 M | USA |
 |
Schrödinger
SDGR
|
132 M | $ 17.19 | -0.81 % | $ 1.25 B | USA |
 |
So-Young International
SY
|
899 M | $ 2.99 | 0.51 % | $ 237 M |  China |
 |
MTBC
MTBC
|
40.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
10x Genomics
TXG
|
409 M | $ 23.08 | -0.47 % | $ 2.7 B | USA |
 |
1Life Healthcare
ONEM
|
145 M | - | - | $ 3.37 B | USA |
 |
GoodRx Holdings
GDRX
|
521 M | $ 2.58 | 0.19 % | $ 995 M | USA |
 |
Omnicell
OMCL
|
471 M | $ 50.66 | -1.3 % | $ 2.33 B | USA |
 |
Premier
PINC
|
199 M | - | - | $ 2.33 B | USA |
 |
Progyny
PGNY
|
63.4 M | $ 24.98 | -0.08 % | $ 2.14 B | USA |
 |
Phreesia
PHR
|
80.1 M | $ 15.79 | -0.03 % | $ 862 M | USA |
 |
R1 RCM
RCM
|
393 M | - | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
8.91 M | $ 0.43 | -5.26 % | $ 2.24 M | China |
 |
NantHealth
NH
|
38.2 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
281 M | - | - | $ 1.6 B | USA |
 |
Streamline Health Solutions
STRM
|
13.3 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
369 M | $ 6.29 | -0.94 % | $ 1.07 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
103 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
1.69 B | $ 223.62 | -0.73 % | $ 35.9 B | USA |
 |
SCWorx Corp.
WORX
|
746 K | $ 0.21 | 15.75 % | $ 306 K | USA |